{"id":"NCT00699153","sponsor":"Bausch & Lomb Incorporated","briefTitle":"Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery","officialTitle":"Safety and Efficacy of Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-06","primaryCompletion":"2009-05","completion":"2009-06","firstPosted":"2008-06-17","resultsPosted":"2010-09-23","lastUpdate":"2015-03-24"},"enrollment":400,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Ocular Inflammation"],"interventions":[{"type":"DRUG","name":"Loteprednol Etabonate","otherNames":[]},{"type":"DRUG","name":"Vehicle of Ophthalmic Loteprednol Etabonate","otherNames":[]}],"arms":[{"label":"Loteprednol Etabonate","type":"EXPERIMENTAL"},{"label":"Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"Evaluation of the clinical safety and efficacy of loteprednol etabonate in an ophthalmic base, when compared to vehicle for the treatment of inflammation following cataract surgery.","primaryOutcome":{"measure":"Participants With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0","timeFrame":"Postoperative day 8 (Visit 5)","effectByArm":[{"arm":"Loteprednol Etabonate","deltaMin":64,"sd":null},{"arm":"Vehicle","deltaMin":23,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":204},"commonTop":["Anterior chamber inflammation","Eye Pain","Corneal Edema","Conjunctival Hyperemia","Ciliary Hyperemia"]}}